Evogene Ltd. EVGN
At closeNov 6, 2026, 6:21 PM EST
After hours · Nov 6, 6:21 PM ET
- YTD
- -75.36%
- 1 year
- -76.64%
- Market cap
- 4.87M
- Revenue (ttm)
- 9.45M
- Profit margin
- -210.25%
- EPS (ttm)
- -1.55
- Shares out
- 6.79M
- Forward P/E
- -0.39
- YTD return
- -75.36%
- 1-year return
- -76.64%
- Volume
- 412.94K
- Avg volume
- 1.50M
- Open
- 0.279
- Previous close
- 0.3216
- Day's range
- 0.2503 – 0.282
- 52-week range
- 0.271 – 1.25
- Beta
- 1.08
- Price target
- 8.13 (+2898.2%)
ALL -95.8704 (-99.66%)
Key statistics
- Enterprise value
- 5.18M
- PEG ratio
- 0.00
- Price / sales
- 0.97
- Price / book
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 39.80%
- Free cash flow
- -2.42M
- Total cash
- 20.91M
- Total debt
- 810.00K
- Return on equity
- -82.37%
- Short % of float
- 0.42%
- 50-day average
- 1.87
- 200-day average
- 4.76
Analyst view
- Target (low)
- 5.00
- Target (mean)
- 8.13
- Target (high)
- 11.25
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.725.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -1.31 | — | — |
| Aug 22, 2024 | Jun 1, 2024 | 0.00 | -1.06 | — | — |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.80 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.40 | -1.30 | +0.10 | +7.14% |
| Nov 15, 2023 | Sep 1, 2023 | -1.70 | -0.80 | +0.90 | +52.94% |
| Aug 17, 2023 | Jun 1, 2023 | -1.90 | -1.70 | +0.20 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | main | Buy | Buy |
| Oct 2, 2023 | Alliance Global Partners | init | — | Buy |
| Aug 18, 2023 | Lake Street | main | Buy | Buy |
| Jul 21, 2023 | Roth MKM | main | Buy | Buy |
| May 2, 2023 | Lake Street | init | — | Buy |
| Sep 12, 2022 | Aegis Capital | main | — | Buy |
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- evogene.com
News
Your note
Sign in to keep a note on EVGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SilverArc Capital Management, LLC | 0.61% | 308,550 | 416.54K | Mar 30, 2024 |
| Morgan Stanley | 0.06% | 28,404 | 38.34K | Mar 30, 2024 |
| BNP Paribas Financial Markets | 0.02% | 9,140 | 12.34K | Mar 30, 2024 |
| LPL Financial LLC | 0.01% | 6,684 | 9.02K | Mar 30, 2024 |
| JP Morgan Chase & Company | 0.01% | 3,943 | 5.32K | Mar 30, 2024 |
| UBS Group AG | 0.01% | 6,250 | 8.44K | Mar 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,901 | 7.97K | May 30, 2024 |